Plasma free amino acid profile in quiescent Inflammatory Bowel Disease patients orally administered with Mastiha (Pistacia lentiscus); a randomised clinical trial

Papada, Efstathia, Amerikanou, Charalampia, Torović, Ljilja, Kalogeropoulos, Nick, Tzavara, Chara, Forbes, Alastair and Kaliora, Andriana C (2019) Plasma free amino acid profile in quiescent Inflammatory Bowel Disease patients orally administered with Mastiha (Pistacia lentiscus); a randomised clinical trial. Phytomedicine, 56. pp. 40-47. ISSN 0944-7113

[img] PDF (Accepted manuscript) - Submitted Version
Restricted to Repository staff only until 13 August 2019.
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (610kB) | Request a copy

    Abstract

    Background: Natural products have been studied regarding their effectiveness on Inflammatory Bowel Disease (IBD). Hypothesis/Purpose: To examine the effects of Mastiha (Pistacia lentiscus var. Chia) on clinical course and amino acid (AA) profile of patients in remission. Study design: This is a randomised, double-blind, placebo-controlled clinical trial. Methods: Patients (N = 68) were randomLy allocated to Mastiha (2.8g/day) or placebo adjunct to sTable medication. Free AAs were identified applying Gas Chromatography-Mass Spectrometry in plasma. Medical-dietary history, Inflammatory Bowel Disease Questionnaire, Harvey-Bradshaw Index, Partial Mayo Score, biochemical, faecal and blood inflammatory markers were assessed. Primary endpoint was the clinical relapse rate at 6 months. Secondary endpoints included variations in free AAs, inflammatory biomarkers and quality of life. Statistical significance was set at 0.05. Results: Concerning AAs and biochemical data, alanine (p = 0.006), valine (p = 0.047), proline (p = 0.022), glutamine (p < 0.001) and tyrosine (p = 0.043) along with total cholesterol (p = 0.032) and LDL cholesterol (p = 0.045) increased only in placebo group compared with baseline and the change between the study groups was significantly different. Inflammatory markers had not a significantly different change between the two groups, even serum IL-6, faecal calprotectin and faecal lactoferrin increased only in the placebo group. Although Mastiha was not proven superior to placebo in remission rate (17.6% vs. 23.5%, p = 0.549), attenuation in increase of free AAs levels in verum group is reported. Conclusion: Mastiha inhibited an increase in plasma free AAs seen in patients with quiescent IBD. Since change of AAs is considered an early prognostic marker of disease activity, this indicates a potential role of Mastiha in remission maintenance.

    Item Type: Article
    Uncontrolled Keywords: free amino acids,inflammatory bowel disease,pistacia lentiscus l.,crude mastiha,remission
    Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
    Depositing User: LivePure Connector
    Date Deposited: 09 Aug 2018 16:30
    Last Modified: 11 Apr 2019 15:58
    URI: https://ueaeprints.uea.ac.uk/id/eprint/68008
    DOI: 10.1016/j.phymed.2018.08.008

    Actions (login required)

    View Item